Overview

An Open-Label Evaluation of the Independent Effects of Coadministration of a High-Fat Meal and Naltrexone Blockade on the Pharmacokinetic Profile of Dilaudid OROS (Hydromorphone HCI) 16mg

Status:
Completed

Trial end date:
1997-06-01

Target enrollment:

Participant gender:

Summary

The purpose of this study was to compare the pharmacokinetic (the way a drug enters and leaves the blood and tissues over time) profile of Dilaudid OROS 16mg (Dilaudid Slow Release; hydromorphone HCL) administered under fasting conditions, following a high-fat breakfast meal. The study also examined the effect of naltrexone blockade on the pharmacokinetic profile of Dilaudid SR.

Phase:

Phase 1

Details

Lead Sponsor:

Alza Corporation, DE, USA

Treatments:

Hydromorphone
Naltrexone
Narcotic Antagonists